Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Giuseppe Luigi BannaMarcello TiseoDiego L CortinovisFrancesco FacchinettiJoachim G J V AertsCinzia BaldessariRaffaele GiustiEmilio BriaFrancesco GrossiRossana BerardiAlessandro MorabitoAnnamaria CatinoCarlo GenovaFrancesca MazzoniAlain GelibterFrancesca RastelliMarianna MacerelliRita ChiariStefania GoriGiovanni MansuetoFabrizio CitarellaLuca CantiniErika RijavecFederica BertoliniFederico CappuzzoAlessandro De TomaAlex FriedlaenderGiulio MetroMaria Vittoria PensieriGiampiero PorzioCorrado FicorellaDavid J PinatoAlessio CortelliniAlfredo AddeoPublished in: Thoracic cancer (2021)
The assessment of pre-existing imbalance of the host immune response by combined blood and clinical immune-inflammatory markers may represent a way to unravel the heterogeneous outcome and assessment of patients with mNSCLC and poor PS in the immune-oncology setting.